Ventus Therapeutics – Talk Bio

Actionable Insights Powered by AI

Ventus Therapeutics Doses First Patient in Phase 2 Trial of VENT-03, an Oral cGAS Inhibitor, in Lupus

2 months ago talkbio0Tagged Autoimmune Diseases, Biological Markers, cardiometabolic, cGAS inhibitor, Clinical Trials, Immunology, inflammaging, interferon pathway, Lupus Erythematosus, Cutaneous, Lupus Vulgaris, oral small molecule, Phase 2 trial, VENT-03, Ventus Therapeutics

Ventus Therapeutics; VENT-03; cGAS inhibitor; Phase 2 trial; lupus; cutaneous lupus erythematosus; autoimmune disease; interferon pathway; biomarkers; oral small molecule; clinical trial; immunology; cardiometabolic; inflammaging

Ventus Therapeutics Continues Phase 2a Trial of VENT-02 NLRP3 Inhibitor in Parkinson’s Disease; No Indication of Program Halt

3 months ago talkbio0Tagged Biological Markers, Clinical Development, Neuroinflammation, NLRP3 inhibitor, Parkinson 's disease, Phase 2a Trial, VENT-02, Ventus Therapeutics

Ventus Therapeutics; VENT-02; NLRP3 inhibitor; Phase 2a trial; Parkinson’s disease; clinical development; neuroinflammation; biomarkers